KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Receivables (2016 - 2025)

Astrazeneca (AZN) has 3 years of Receivables data on record, last reported at $12.3 billion in Q4 2025.

  • For Q4 2025, Receivables fell 15.79% year-over-year to $12.3 billion; the TTM value through Dec 2025 reached $12.3 billion, down 15.79%, while the annual FY2025 figure was $12.3 billion, 15.79% down from the prior year.
  • Receivables reached $12.3 billion in Q4 2025 per AZN's latest filing, down from $14.6 billion in the prior quarter.
  • Across five years, Receivables topped out at $14.6 billion in Q4 2024 and bottomed at $10.0 billion in Q4 2023.
  • Average Receivables over 3 years is $12.3 billion, with a median of $12.3 billion recorded in 2025.
  • Peak YoY movement for Receivables: skyrocketed 44.84% in 2024, then fell 15.79% in 2025.
  • A 3-year view of Receivables shows it stood at $10.0 billion in 2023, then surged by 44.84% to $14.6 billion in 2024, then dropped by 15.79% to $12.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $12.3 billion in Q4 2025, $14.6 billion in Q4 2024, and $10.0 billion in Q4 2023.